Lataa...

SARS-CoV-2 vaccination in IBD: more pros than cons

Data on the efficacy and safety of SARS-CoV-2 vaccines are now available, but evidence for these vaccines in those who are immunocompromised (including patients with inflammatory bowel diseases) are lacking. As vaccination begins, questions on advantages and disadvantages can be partially addressed...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Nat Rev Gastroenterol Hepatol
Päätekijät: D’Amico, Ferdinando, Rabaud, Christian, Peyrin-Biroulet, Laurent, Danese, Silvio
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group UK 2021
Aiheet:
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7816748/
https://ncbi.nlm.nih.gov/pubmed/33473178
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41575-021-00420-w
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!